"目录号: HY-14463
Cell Cycle/DNA DamageMetabolic Enzyme/Protease-
AT13387是Hsp90抑制剂，对A375细胞的IC50为18 nM，具有长效的抗肿瘤活性。
相关产品
17-AAG-Triptolide-NVP-AUY922-Ganetespib-Geldanamycin-Teprenone-Rocaglamide-VER-155008-Retaspimycin Hydrochloride-Alvespimycin hydrochloride-Debio 0932-BIIB021-PU-H71-NVP-HSP990-Apoptozole-
生物活性
Description
AT13387 is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity.IC50 Value: 18 nM Target: Hsp90in vitro: AT13387 is a synthetic, orally bioavailable, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor AT13387 selectively binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability and degradation of many oncogenic signaling proteins. AT13387 is a selective potent heat shock protein 90 (Hsp90) inhibitor with IC50 of 18 nM in A375 cells. The Kd for AT13387 binding is 0.7 nM.in vivo: AT13387 could be tolerated at doses of up to 70 mg/kg twice weekly or 90 mg/kg once weekly. Body weight loss in mice does not exceed 20% before recovering in all cases except one, and loss is highest following the second dose. Tumor growth inhibition is similar in NCI-H1975 for both dosing regimens. The maintenance of antitumor effects with such a prolonged off-treatment period is consistent with the extended pharmacodynamic action of AT13387 observed for mutant EGFR and other biomarkers in vitro and in vivo and the extended retention of AT13387 in tumors.
Clinical Trial
Astex Pharmaceuticals
Gastrointestinal Stromal Tumor (GIST)
March 2011
Phase 2
Astex Pharmaceuticals
Non-small Cell Lung Cancer(NSCLC)
October 2012
Phase 1-Phase 2
National Cancer Institute (NCI)-National Institutes of Health Clinical Center (CC)
Solid Tumors-Breast Cancer
November 1, 2010
Phase 1
Astex Pharmaceuticals
Prostate Cancer
September 2012
Phase 1-Phase 2
National Cancer Institute (NCI)
Adult Solid Neoplasm-Estrogen Receptor Negative-Fallopian Tube Serous Neoplasm-HER2/Neu Negative-Ovarian Serous Adenocarcinoma-Ovarian Serous Tumor-Primary Peritoneal Serous Adenocarcinoma-Progesterone Receptor Negative-Recurrent Breast Carcinoma-Recurrent Fallopian Tube Carcinoma-Recurrent Ovarian Carcinoma-Recurrent Primary Peritoneal Carcinoma-Triple-Negative Breast Carcinoma
March 2016
Phase 1
Astex Pharmaceuticals
Metastatic Solid Tumors
May 2008
Phase 1
Astex Pharmaceuticals
Gastrointestinal Stromal Tumor (GIST)
March 2011
Phase 2
Astex Pharmaceuticals
Non-small Cell Lung Cancer(NSCLC)
October 2012
Phase 1-Phase 2
National Cancer Institute (NCI)-National Institutes of Health Clinical Center (CC)
Solid Tumors-Breast Cancer
November 1, 2010
Phase 1
Astex Pharmaceuticals
Prostate Cancer
September 2012
Phase 1-Phase 2
National Cancer Institute (NCI)
Adult Solid Neoplasm-Estrogen Receptor Negative-Fallopian Tube Serous Neoplasm-HER2/Neu Negative-Ovarian Serous Adenocarcinoma-Ovarian Serous Tumor-Primary Peritoneal Serous Adenocarcinoma-Progesterone Receptor Negative-Recurrent Breast Carcinoma-Recurrent Fallopian Tube Carcinoma-Recurrent Ovarian Carcinoma-Recurrent Primary Peritoneal Carcinoma-Triple-Negative Breast Carcinoma
March 2016
Phase 1
Astex Pharmaceuticals
Metastatic Solid Tumors
May 2008
Phase 1
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm-Metastatic Malignant Solid Neoplasm-Unresectable Solid Neoplasm
April 8, 2016
Phase 1
National Cancer Institute (NCI)
ALK Positive-BCL6 Positive-Recurrent Anaplastic Large Cell Lymphoma-Recurrent Diffuse Large B-Cell Lymphoma-Recurrent Mantle Cell Lymphoma-Refractory Anaplastic Large Cell Lymphoma-Refractory Diffuse Large B-Cell Lymphoma-Refractory Mantle Cell Lymphoma
April 4, 2016
Phase 2
National Cancer Institute (NCI)
EGFR Activating Mutation-EGFR Exon 20 Insertion Mutation-Recurrent Non-Small Cell Lung Carcinoma-Stage IV Non-Small Cell Lung Cancer AJCC v7
January 21, 2016
Phase 1-Phase 2
National Cancer Institute (NCI)
Estrogen Receptor Negative-HER2/Neu Negative-Progesterone Receptor Negative-Recurrent Breast Carcinoma-Stage III Breast Cancer-Stage IIIA Breast Cancer-Stage IIIB Breast Cancer-Stage IIIC Breast Cancer-Stage IV Breast Cancer-Triple-Negative Breast Carcinoma
January 15, 2016
Phase 1
National Cancer Institute (NCI)
BRAF V600E Mutation Present-BRAF V600K Mutation Present-Metastatic Malignant Solid Neoplasm-Recurrent Malignant Solid Neoplasm-Recurrent Melanoma-Stage III Skin Melanoma-Stage IIIA Skin Melanoma-Stage IIIB Skin Melanoma-Stage IIIC Skin Melanoma-Stage IV Skin Melanoma-Unresectable Solid Neoplasm
May 29, 2014
Phase 1
National Cancer Institute (NCI)
Estrogen Receptor Negative-HER2/Neu Negative-High Grade Fallopian Tube Serous Adenocarcinoma-High Grade Ovarian Serous Adenocarcinoma-Metastatic Malignant Solid Neoplasm-Primary Peritoneal High Grade Serous Adenocarcinoma-Progesterone Receptor Negative-Recurrent Breast Carcinoma-Recurrent Fallopian Tube Carcinoma-Recurrent Ovarian Carcinoma-Recurrent Primary Peritoneal Carcinoma-Triple-Negative Breast Carcinoma-Unresectable Solid Neoplasm
May 19, 2017
Phase 1
National Cancer Institute (NCI)
Human Papillomavirus Infection-Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7-Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7-Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7-Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7-Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7-Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7-Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7-Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7-Stage IVB
September 21, 2015
Phase 1
View MoreCollapse
References
[5].Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors
